Allianz Asset Management GmbH grew its stake in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) by 2.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 462,105 shares of the biotechnology company’s stock after buying an additional 9,985 shares during the quarter. Allianz Asset Management GmbH owned 0.53% of Arrowhead Pharmaceuticals worth $1,701,000 at the end of the most recent reporting period.
Several other institutional investors also recently added to or reduced their stakes in ARWR. ING Groep NV acquired a new position in shares of Arrowhead Pharmaceuticals in the third quarter valued at approximately $3,500,000. Schwab Charles Investment Management Inc. boosted its holdings in Arrowhead Pharmaceuticals by 10.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock worth $742,000 after purchasing an additional 16,103 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Arrowhead Pharmaceuticals by 252.2% during the third quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 31,765 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Arrowhead Pharmaceuticals by 1,177.7% during the fourth quarter. Acadian Asset Management LLC now owns 71,664 shares of the biotechnology company’s stock worth $264,000 after purchasing an additional 66,055 shares during the last quarter. Finally, First Manhattan Co. acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter worth $11,707,000. Institutional investors own 26.88% of the company’s stock.
Several research analysts recently commented on ARWR shares. BidaskClub upgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 1st. Chardan Capital restated a “buy” rating and set a $7.00 target price on shares of Arrowhead Pharmaceuticals in a report on Monday, February 19th. Piper Jaffray Companies upgraded shares of Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 target price for the company in a report on Monday, November 27th. Cantor Fitzgerald set a $5.00 target price on shares of Arrowhead Pharmaceuticals and gave the stock a “neutral” rating in a report on Monday, February 12th. Finally, ValuEngine upgraded shares of Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. Four research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $4.70.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Friday, February 9th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.04). The firm had revenue of $3.51 million during the quarter, compared to analyst estimates of $8.71 million. Arrowhead Pharmaceuticals had a negative net margin of 116.17% and a negative return on equity of 42.52%. analysts forecast that Arrowhead Pharmaceuticals Inc will post -0.71 EPS for the current fiscal year.
In other Arrowhead Pharmaceuticals news, COO Bruce D. Given sold 20,000 shares of the stock in a transaction on Monday, March 5th. The shares were sold at an average price of $6.73, for a total value of $134,600.00. Following the completion of the sale, the chief operating officer now owns 908,356 shares in the company, valued at $6,113,235.88. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Christopher Richard Anzalone sold 100,000 shares of the stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $7.43, for a total transaction of $743,000.00. Following the completion of the sale, the chief executive officer now owns 2,194,789 shares of the company’s stock, valued at approximately $16,307,282.27. The disclosure for this sale can be found here. In the last quarter, insiders sold 440,000 shares of company stock valued at $3,180,400. Corporate insiders own 4.60% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Arrowhead Pharmaceuticals Inc (ARWR) Shares Bought by Allianz Asset Management GmbH” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3294923/arrowhead-pharmaceuticals-inc-arwr-shares-bought-by-allianz-asset-management-gmbh.html.
Arrowhead Pharmaceuticals Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.